Page 259 - medicina-integrativa_compress

CAPÍTULO 23 HEPATITIS CRÓNICA 253

riesgo concomitante de transformación Precauciones
maligna. Las mismas precauciones que se
mencionaron para el interferón pegilado.
Dosis
15 μg de interferón alfacon-1 dos veces a la
semana por vía subcutánea. B B 2 2

BIBLIOGRAFÍA 22. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C.
Hepatology 36(Suppl 1):S121-S127, 2002.
1. Centers for Disease Control and Prevention: Recommendations for 23. Napoli N, Giannelli G, Parisi CV, et al: Predictive value of early
prevention and control of hepatitis C virus (HCV) infection and virological response to treatment with different interferon-based
HCV-related chronic disease. MMWR 47(No. RR-19):1-33, 1998. regimens plus ribavirin in patients with chronic hepatitis C. N
2. Centers for Disease Control and Prevention: National Hepatitis C Microbiol 28:13-21, 2005.
Prevention Strategy: A Comprehensive Strategy for the Prevention 24. Manns M, McHutchison J, Gordon S, et al: Peginterferon alfa-2b
and Control of Hepatitis C Virus Infection and Its Consequences. plus ribavirin compared with interferon alfa-2b plus ribavirin for
Atlanta, Division of Viral Hepatitis, National Center for Infectious initial treatment of chronic hepatitis C: A randomized trial. Lancet
Diseases, Centers for Disease Control and Prevention, Summer 2001. 358:958-965, 2001.
3. Saleem N, Mubarik A, Qureshi AH, et al: Is there a correlation 25. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a
between degree of viremia and liver histology in chronic hepatitis C? and ribavirin combination therapy in chronic hepatitis C:
J Pak Med Assoc 54:476-479, 2004. A randomized study of treatment duration and ribavirin dose.
4. Rodriguez-Inigo E, Bartolome J, deLucas S, et al: Histological Ann Intern Med 140:346-355, 2004.
damage in chronic hepatitis C is not related to the extent of 26. Veldt BJ, Saracco G, Boyer N, et al: Long-term clinical outcome
infection in the liver. Am J Pathol 154:1877-1881, 1999. of chronic hepatitis C patients with sustained virological response
5. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the to interferon monotherapy. Gut 53:1504-1508, 2004.
United States. Hepatology 36(5 Suppl 1):S74-S83, 2002. 27. Droge W, Pottmeyer-Gerber C, Schmidt H: Glutathione augments
6. Poynard T, Bedossa P, Opolon P, et al: Natural history of liver the activation of cytotoxic T lymphocytes in vivo. Immunobiology
fibrosis progression in patients with chronic hepatitis C. Lancet 172:151-156, 1986.
349:825-832, 1997. 28. Loguercio C, Blanco FD, De Girolamo V: Ethanol consumption,
7. Alberti A, Benvegnu L, Boccato S, et al: Natural history of initially amino acid, and glutathione blood levels in patients with and
mild chronic hepatitis C. Dig Liver Dis 36:646-654, 2004. without chronic liver disease. Alcohol Clin Exp Res 23:1780-1784,
8. Kleiner DE: The liver biopsy in chronic hepatitis C: A view from the 1999.
other side of the microscope. Semin Liver Dis 25:52-64, 2005. 29. Barbaro G, Di Lorenzo G, Soldini M: Hepatic glutathione deficiency
9. National Institutes of Health. Management of Hepatitis C: 2002 in chronic hepatitis C: Quantitative evaluation in patients who are
National Institutes of Health Consensus Conference Statement. HIV positive and HIV negative and correlations with plasmatic and
Available online as of September 2005 at lymphocytic concentrations and with the activity of the liver disease.
http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm. Am J Gastroenterol 91:2569-2573, 1996.
10. Strader DB,Wright T, Thomas DL, Seeff LB: Diagnosis, 30. Witschi A, Reddy S, Stofer B, Lauterburg BH: The systemic
management, and treatment of hepatitis C. Hepatology availability of oral glutathione. Eur J Clin Pharmacol 43:667-669,
39:1147-1171, 2004. 1992.
11. Cotran RS, Kumar V, Robbins SL(eds): Inflammation and repair. 31. Johnston CJ, Meyer CG, Srilakshmi JC: Vitamin C elevates red blood
In Robbins Pathologic Basis of Disease, 5th ed. Philadelphia, cell glutathione in healthy adults. Am J Clin Nutr 58:103-105, 1993.
WB Saunders, 1994, pp 51-92. 32. Von Herbay A, Stahl W, Niederau C, Sies H: Vitamin E improves the
12. Lechner F, Wong DK, Dunbar PR, et al: Analysis of successful aminotransferase status of patients suffering from viral hepatitis C:
immune responses in persons infected with hepatitis C virus. A randomized, double-blind, placebo controlled study. Free Radical
J Exp Med 191:1499-1512, 2000. Res 27:599-605, 1997.
13. Shoukry NH, Grakoui A, Houghton M, et al: Memory CD8 + 33. Look MP, Gerard A, Rao GS, et al: Interferon/antioxidant
T cells are required for protection from persistent hepatitis C virus combination therapy for chronic hepatitis C: A controlled pilot
infection. J Exp Med 197:1645-1655, 2003. trial. Antiviral Res 43:113-122, 1999.
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
14. Thimme R, Oldach D, Chang KM, et al: Determinants of viral 34. Chojkier M, Houglum K, Lee KS, Buck M: Long- and short-term
clearance and persistence during acute hepatitis C virus infection. D-α-tocopherol supplementation inhibits liver collagen a1(I) gene
J Exp Med 194:1395-1406, 2001. expression. Am J Physiol 275:G1480-G1485, 1998.
15. Cramp ME, Rossol S, Chokshi S, et al: Hepatitis C virus-specific 35. Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study
T-cell reactivity during interferon and ribavirin treatment in of the effects of D-alpha-tocopherol on hepatic stellate cell activation
chronic hepatitis C. Gastroenterology 118:346-355, 2000. in chronic hepatitis C. Gastroenterology 113:1069-1073, 1977.
16. Kamal SM, Fehr J, Roesler B, et al: Peginterferon alone or 36. Jain A, Buist NR, Kennaaway NG, et al: Effect of ascorbate or
with ribavirin enhances HCV-specific CD4 T-helper 1 responses N-acetylcysteine treatment in a patient with hereditary
in patients with chronic hepatitis C. Gastroenterology glutathione synthetase deficiency. J Pediatr 124:229-233, 1994.
123:1070-1083, 2002. 37. Kleinveld HA, Demacker PNM, Stalenhoef AFH: Failure of
17. Reiser M, Marousis CG, Nelson DR, et al: Serum interleukin 4 N-acetylcysteine to reduce low-density lipoprotein oxidizability
and interleukin 10 levels in patients with chronic hepatitis C virus in healthy subjects. Eur J Clin Pharmacol 43:639-642, 1992.
infection. J Hepatol 26:471-478, 1997. 38. Beloqui O, Prieto J, Suarez M, et al: N-acetylcysteine enhances the
18. He XS, Rehermann B, Lopez-Labrador FX, et al: Quantitative response to interferon-alpha in chronic hepatitis C: A pilot study.
analysis of hepatitis C virus-specific CD8 + T cells in peripheral J Interferon Res 13:279-282, 1993.
blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci 39. Ideo G, Bellobuono A, Tempini S, et al: Antioxidant drugs
U S A 96:5692-5697, 1999. combined with alpha-interferon in chronic hepatitis C not
19. Mayo MJ: Extrahepatic manifestations of hepatitis C infection. responsive to alpha-interferon alone: A randomized, multicentre
Am J Med Sci 325:135-148, 2002. study. Eur J Gastroenterol Hepatol 11:1203-1207, 1999.
20. Pizzourno JE, Murray MT (eds): Detoxification. In Textbook of 40. Look MP, Gerard A, Rao GS, et al: Interferon/antioxidant
Natural Medicine, 2nd ed. Edinburgh, Churchill-Livingstone, 1999. combination therapy for chronic hepatitis C: A controlled pilot trial.
21. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus Antiviral Res 43:113-122, 1999.
ribavirin for chronic hepatitis C virus infection. N Engl J Med 41. Bernhard MC, Junker E, Hettinger A, et al: Time course of total
347:975-982, 2002. cysteine, glutathione, and homocysteine in plasma of patients with